Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolysis in acute ischemic stroke

A Luisi1, A L Hume

  • 1Department of Pharmacy, University of Rhode Island, Kingston 02881, USA.

The Journal of the American Board of Family Practice
|June 6, 1998
PubMed
Summary

Early treatment with recombinant tissue plasminogen activator (rt-PA) can improve outcomes for acute ischemic stroke patients. Strict adherence to eligibility criteria and a 3-hour window are crucial for safe and effective rt-PA administration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonhormonal management of postmenopausal women: effects of a red clover based isoflavones supplementation on climacteric syndrome and cardiovascular risk serum profile.

Clinical and experimental obstetrics & gynecology·2013
Same author

Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome.

Clinical and experimental obstetrics & gynecology·2013
Same author

Arterial hypertension and female sexual dysfunction in postmenopausal women.

Clinical and experimental obstetrics & gynecology·2013
Same author

Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort.

Pharmacotherapy·2001
Same author

Pharmacologic treatment of diabetes in long-term care.

Journal of clinical epidemiology·2001
Same author

Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.

International journal of cancer·2000

Area of Science:

  • Neurology
  • Emergency Medicine
  • Pharmacology

Background:

  • Acute ischemic stroke requires timely intervention to mitigate brain damage.
  • Recombinant tissue plasminogen activator (rt-PA) is a key thrombolytic therapy.
  • Optimizing rt-PA use in clinical practice is essential for patient benefit.

Purpose of the Study:

  • To outline the critical criteria for the safe and effective administration of rt-PA.
  • To emphasize the importance of early presentation and symptom onset definition.
  • To detail the recommended dosage and infusion protocol for rt-PA.

Main Methods:

  • Review of established guidelines for rt-PA administration.
  • Emphasis on patient selection based on symptom onset and contraindications.
  • Description of the standard rt-PA dosage and intravenous infusion procedure.

Main Results:

  • Successful rt-PA administration requires early patient presentation and symptom onset.
  • Exclusion of hemorrhage via CT scan is a mandatory prerequisite.
  • Adherence to the 0.9 mg/kg dosage (max 90 mg) and 3-hour window is critical.

Conclusions:

  • rt-PA offers significant potential for improving functional outcomes in acute ischemic stroke.
  • Strict adherence to patient selection criteria and treatment window is paramount for safety and efficacy.
  • While not all patients meet trial criteria, rt-PA represents a major therapeutic advance.

Related Experiment Videos